WASHINGTON — Reduced doses of radiation therapy and immunotherapy did not work as well as the standard chemoradiation for early-stage HPV-associated oropharyngeal cancer, in a new […]

The US Food and Drug Administration (FDA) has expanded the approval of nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of certain patients with resectable non–small […]

BARCELONA — Intravenous patient-controlled administration of hydromorphone offers better pain control and higher patient satisfaction compared with conventional oral morphine in managing severe cancer pain, according […]

BARCELONA, Spain — Ethnic Chinese immigrants affected by cancer are a particularly vulnerable group and may face significant barriers to receiving proper diagnosis and treatment, according […]

WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial […]

WASHINGTON — A phase 2 study has demonstrated encouraging results for lutetium-177 (177Lu) dotatate in patients with surgery- and radiation-refractory meningioma. Kenneth Merrell, MD, MS, presented […]

About 40% of patients with brain metastases who experienced cognitive decline after brain radiation therapy regained full cognitive function within 6 months following treatment, a new […]

BARCELONA, Spain — Trastuzumab deruxtecan (TDXd) shows promise as a treatment for HER2-low and HER2-ultralow hormone receptor (HR)–positive metastatic breast cancer, according to data from the […]

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, […]